A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder
NCT04007367
·
clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
53
Enrollment
INDUSTRY
Sponsor class
Stopped
Internal company decision
Conditions
Major Depressive Disorder
Interventions
DRUG:
SAGE-217
DRUG:
Placebo
Sponsor
Biogen